twoXAR Appoints Brian Moriarty As CFO And Jill Jene, PhD, As SVP, Business Development

PALO ALTO, Calif.--(BUSINESS WIRE)--twoXAR, Inc., a company dedicated to improving health through computation, today announced the appointment of Brian Moriarty as Chief Financial Officer and Jill Jene, PhD as Senior Vice President, Business Development. In addition, co-founder and former Chief Business Officer, Andrew M. Radin has been named to the newly created position of Chief Marketing Officer.

“We are pleased to welcome Jill and Brian to the twoXAR management team,” said Andrew A. Radin, co-founder and Chief Executive Officer of twoXAR. “Their leadership and expertise in finance, operations, and business development will support our growing pipeline of partnerships and drug candidates, positioning twoXAR for success over the years to come.”

Prior to joining twoXAR, Mr. Moriarty advised small and mid-size companies on strategic matters, led M&A activity as a corporate development executive, and advised clients as an investment banker. His 20+ year career includes: CFO of ChartOne, Vice President at Hewlett-Packard where he supported HP’s separation into two publicly-traded companies and led the HR group responsible for M&A and outsourcing; Vice President of M&A at Sun Microsystems where he led 17 acquisitions and helped the company sell itself to Oracle Corporation; and ten years as an investment banker advising clients. Mr. Moriarty holds a Master of Management from Northwestern University and a BA in English and economics from the University of California, Davis.

Dr. Jene brings nearly 20 years of business development expertise in the life science and biopharmaceutical industries and a deal sheet totaling over $3 Billion to her new role at twoXAR. She joins twoXAR from Depomed, Inc. where she was the Vice President Business Development, closing over 20 transactions resulting in raising over $750 Million in non-dilutive financing and acquiring four commercial franchises. With almost 20 years of experience in the healthcare and biotech industry, Dr. Jene has an established track record for closing transactions, both acquisitions and divestitures.

Prior to joining Depomed, Dr. Jene held business and corporate development roles with increasing responsibilities at Baxter, Cell Genesys (acquired by Biosante), and 3M Pharmaceutical Division (now Valeant). Dr. Jene earned a BS in chemistry from Bradley University graduating, with honors, and holds both a PhD and MS in chemistry from Northwestern University and an MBA in strategic management from DePaul University.

About twoXAR

twoXAR is an artificial intelligence-driven biopharmaceutical company. The company leverages its computational platform to identify promising drug candidates, de-risks the opportunities through preclinical studies, and progresses drug candidates to the clinic through industry partnerships. Based in Palo Alto, California, the twoXAR team includes experts in drug discovery and development, biomedical informatics, computational biology, data science, and software development. For more information, please visit www.twoXAR.com.